Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_54dcf7b213723efceaeed28b9d494524 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2821 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-988 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S435-975 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-9015 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
filingDate |
2002-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2006-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cfd46c45bad89009caa0826c579f2f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eec1464a83685576156d6849651f521 |
publicationDate |
2006-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-7070945-B2 |
titleOfInvention |
Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment |
abstract |
A method for determining those patients suffering from mild cognitive impairment (MCI) who have a likelihood of progressing to Alzheimer's disease (AD) is disclosed. The method involves directly detecting the presence of a biochemical marker, specifically human glutamine synthetase, in bodily fluid, preferably blood or a blood product. The detection is by an immunoassay incorporating an antibody specific to human glutamine synthetase. In addition, a method for distinguishing between AD and non-AD dementia is disclosed. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8577106-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011202284-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9086408-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8389226-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9791437-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010124756-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011212854-A1 |
priorityDate |
2001-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |